Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6359841 | 0.81 | PKM (0.53) | HPGDKMT2AMAPTLMNAMEN1 | |
| SCHEMBL17448042 | 0.75 | TP53 (0.44) | TP53KMT2A | |
| SCHEMBL8577254 | 0.74 | RAB9A (0.45) | TP53KMT2AMAPTMEN1 | |
| SCHEMBL6678033 | 0.74 | RAB9A (0.45) | TP53KMT2AMAPTMEN1 | |
| SCHEMBL1519203 | 0.74 | FFAR2 (0.45) | TP53 | |
| SCHEMBL8580943 | 0.74 | FFAR2 (0.45) | TP53 | |
| SCHEMBL8576142 | 0.74 | FFAR2 (0.45) | TP53 | |
| SCHEMBL31303534 | 0.73 | TP53 (0.41) | HPGDTP53MAPT | |
| SCHEMBL8568422 | 0.72 | MTNR1A (0.51) | HPGDKMT2AMAPTLMNATDP1 | |
| SCHEMBL8568425 | 0.72 | MTNR1A (0.51) | HPGDKMT2AMAPTLMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210220408-A1 | ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE | EDIGENE BIOTECHNOLOGY, INC. (CN) | 2021-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220408-A1 | ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE | AHR, ARNT, ARSA | HPGD 512/4885TP53 1313/4885KMT2A 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.